Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of cases and controls

From: Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study

Characteristics Cases Controls
(n = 90) (n = 90)
Female, n (%) 78 (87) 78 (87)
Age (years), mean (SD) 60 (15) 59 (16)
Race, n (%)   
  Caucasian 76 (84)  
  Asian 9 (10)  
  Other 5 (6)  
Duration of disease (years), mean (SD) 14.3 (10.3)  
SSc subtype, n (%)   
  Diffuse disease 23 (26)  
  Limited disease 62 (69)  
  Sine 1 (1)  
  Mixed connective tissue disease 4 (4)  
Autoantibodies, n (%)   
  Anti-topoisomerase I (Scl-70) 17 (19)  
  Anti-centromere 38 (42)  
  Anti-RNA polymerase III 8 (9)  
Organ involvement, n (%)   
  Bowel dysmotility 9 (10)  
  Pulmonary arterial hypertension 8 (9)  
  Interstitial lung disease 41 (46)  
  Renal crisis 4 (4)  
  Gastroesophageal reflux disease 83 (92)  
Disease activity/severity   
  Active digital ulcers, n (%) 13 (14)  
  mRSS, mean (SD) 8.9 (7.3)  
  SSc HAQ, mean (SD) 20.5 (13.4)  
  EUSTAR SSc activity score, mean (SD) 2.2 (1.7)  
  Immunosuppressive agents, n (%) 28 (31)  
  Past treatment with iloprost, n (%) 17 (19)  
  FVC (% predicted), mean (SD) 91.5 (22.5)  
  DLCO (% predicted), mean (SD) 58.5 (18.8)  
  6MWD (meter), mean (SD) meters 471.7 (126.1)  
  1. 6MWD, six-minute walk distance; DLCO, diffusing capacity of the lung for carbon monoxide; EUSTAR, EULAR Scleroderma Trials and Research Group; FVC, forced vital capacity; mRSS, modified Rodnan skin score; SD, standard deviation; SSc, systemic sclerosis; SSc HAQ, Scleroderma Health Assessment Questionnaire.